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Photodynamic therapy in gastroenterology Photodynamic therapy (PDT) is a technique for producing local necrosis of tissue with low power light (most conveniently from a laser) after prior administration of a photosensitising drug.' It is a photochemical rather than a thermal effect and the presence of oxygen is essential as the cytotoxic intermediary is the reactive species, singlet oxygen.2 Although the principles of PDT are straightforward, a full understanding requires knowledge of physics, chemistry and photobiology, and applying it to best effect requires close collaboration between scientists and clinicians. PDT has attracted a lot of interest as many photosensitising agents are taken up with some degree of selectivity by malignant tumours, which raised the possibility of ablating cancers without damaging the surrounding normal tissue. Unfortunately, it is now clear that in general terms, this was over optimistic, but PDT is proving valuable for other reasons, mainly related to the nature of the tissue damage produced and the subsequent excellent healing.3
Early clinical reports on PDT for advanced cancers of the oesophagus, stomach and colon using the photosensitiser haematoporphyrin derivative were anecdotal. A few millimetres were removed from the surface of advanced tumours at the price of two to three months skin photosensitivity to sunlight, with a functional result that could probably have been achieved with lower morbidity using other techniques like the Nd:YAG laser or a stent.45 One paper reported increased effects on oesophageal cancer with a higher laser power, but the effects described were almost certainly thermal and not PDT, and would probably have been seen even if the patients had not been photosensitised prior to laser treatment.6 Initial clinical enthusiasm waned while the scientists tried to understand more about the biological effects involved.
PDT experiments on normal colon and colon cancers growing in the colon (rather than the non-physiological situation of tumours transplanted subcutaneously) were first reported only about 10 They treated 123 patients between 1983 and 1991 with Ti and T2 adeno-and squamous carcinomas who were unfit for surgery. The complete response rate at six months was 87%. The overall five year survival was 25%, but the five year disease specific survival was 75%, confirming the efficacy of PDT in appropriately selected patients. The photosensitiser used was haematoporphyrin derivative, and as might have been expected, oesophageal stenosis was seen in 43 (35%) patients, but all responded to dilation. Japanese groups realised the potential for treating early gastric cancers at a very early stage.'2 Barr et al quantified the effects in small colonic tumours with endoscopic ultrasound. 13 Recently, there has been renewed interest in PDT for palliation of advanced oesophageal cancers, perhaps partly as a way of getting some application of PDT approved by the Food and Drugs Administration (FDA) in the USA.'6 17 The most comprehensive report is a phase III, randomised, multicentre study comparing PDT using Photofrin to Nd:YAG laser therapy in 236 patients with advanced malignant dysphagia from Lightdale et al. '6 The response rates, median survival times (PDT: 123 days; Nd:YAG: 140 days), time to palliation failure (PDT: 34 days; Nd:YAG: 42 days) and dysphagia scores were similar for both groups, although the authors admit that their response rates in the Nd:YAG laser group (48% at one week and 29% at one month) are way below the figures of 65-80% in most other studies. They reported fewer treatment endoscopies with PDT, but including the debridement endoscopies required after each PDT treatment, the total number of procedures was similar for both. Overall, the incidence of severe complications was the same in both groups. The only complication seen more frequently in the Nd:YAG laser group was perforation, which occurred in 7%, half of which were associated with dilation. Again, they comment that this is higher than the perforation rate of 0-5% reported by others using the Nd:YAG laser. Of the patients undergoing PDT, 19% had sunburn and all had cutaneous photosensitivity for one to two months. Follow up data were not available for 22% of patients at one week and 39% at one month. These results do not paint a convincing picture of the superiority of PDT in this situation! Nevertheless, the FDA has now approved PDT with Photofrin for the palliation of advanced oesophageal cancer if no alternative treatment is available. It is understandable that they have chosen this "last ditch" situation as the first for approval, but in our experience, there are very few patients whose dysphagia cannot be relieved just as effectively and safely by other means without making them photosensitive for much of their remaining life. On purely scientific grounds, the approval of the Japanese authorities for PDT with Photofrin for the treatment of early oesophageal cancers is more logical. PDT has not yet been approved for any application in the United Kingdom, although it has been approved for early and advanced oesophageal cancers in Leading articles express the views of the author and not those of the editor and editorial board.
The Netherlands and for advanced oesophageal cancers in France.
Although Photofrin is the only photosensitiser yet to receive regulatory approval in any country, it is unlikely to be used widely because of the associated long period of skin photosensitivity. Several second generation drugs are now entering clinical trials, including mTHPC (meso tetrahydroxyphenyl chlorin), Sn Et2 (tin etiopurpurin), BPDMA (benzo-porphyrin derivative mono acid), and AlSPc (aluminium disulphonate.d phthalocyanine).'5 However, one of the most interesting is ALA (5-aminolaevulinic acid) which is converted in vivo into the photoactive derivative, protoporphyrin IX (PPIX, the last intermediary before haem). 9 In contrast to other photosensitisers, many of which localise predominantly in the microvasculature of the submucosa of hollow organs like the gastrointestinal tract, PPIX builds up to much higher levels in the mucosa than in the submucosa or muscle. It has been shown experimentally that this can be exploited to achieve selective mucosal necrosis and leave the underlying muscle undamaged,20 as is required to treat areas of mucosal disease. Clinically, this is only of value if necrosed dysplastic mucosa heals with regeneration of normal mucosa, but this has now been described in the treatment of severe dysplasia in Barrett's oesophagus with PDT using ALA. No strictures were seen (in contrast to the results with Photofrin"), although there has been concern that superficial healing could mask underlying severely dysplastic epithelium and further long term evaluation is needed.2' On current knowledge, it is unlikely that PDT with ALA will be effective for disease that has spread deeper than the mucosa, although this might be possible by giving it intravenously to increase the dose that can be tolerated and by fractionating the light.22 The other major advantage of ALA is that skin photosensitivity only lasts for one to two days.2'
Thus PDT with ALA is quite different to PDT with the other currently available photosensitisers. This can be called selective PDT but it must be stressed that the selectivity is between the mucosa and the underlying submucosa and muscle and not between normal and neoplastic mucosa. Normal and abnormal mucosa are necrosed equally effectively if exposed to the same light dose. The principle of ALA PDT can be applied to the treatment of dysplasia in essentially all of the hollow organs of the body. PDT with other photosensitisers can be referred to as non-selective as the necrosis is similar in tumour and in all the layers of the normal wall of the gastrointestinal tract exposed to comparable light doses.
Looking outside the luminal gut, PDT experiments on transplanted cancers in the rat and hamster pancreas have shown better selectivity. It has proved possible to produce necrosis in the tumours without serious damage to the immediately adjacent normal pancreas with several sensitisers. Using pheophorbide A, some animals were tumour free at 120 days,23 and using ALA, there was a significant increase in survival compared with untreated control animals.24 Selectivity of uptake of sensitisers was comparable to the colon, but it was postulated that something in normal pancreas (perhaps glutathione), not present in the cancer, might quench the cytotoxic intermediary, singlet oxygen.25 The normal tissues around the pancreas in hamsters are able to tolerate PDT, with the exception of the duodenum, although no problems have been reported treating the much thicker human duodenum.26 This opens up exciting possibilities for a new approach to treating small cancers localised to the pancreas in patients unsuitable for surgery. Multiple fibres for light delivery could be positioned percutaneously with ultrasound or computed tomography guidance. PDT also has potential for tumours of the ampulla and bile duct.26
In theory, PDT is attractive as adjuvant treatment to pick up microscopic deposits of tumour left after surgery. As selectivity of tumour necrosis is so poor, this will almost certainly necessitate necrosis of a superficial layer of normal tissue as well, but as healing after damage to many normal tissues is so good with regeneration rather than scarring, this will often be acceptable. A randomised, controlled trial has been undertaken applying PDT to the tumour bed after resection of colorectal cancers, but unfortunately has shown no improvement in survival or local recurrence in the PDT group, perhaps because of caution on drug and light doses so as not to cause unacceptable damage to normal tissues.27
The first description of PDT nearly 100 years ago was of killing bacteria, and there is now interest in using PDT to treat localised infections. For gastroenterologists, the obvious target is Helicobacter pylori. Antibiotic regimens can eradicate H pylori in more than 90% of cases, but this is not without risk. The increasing use of systemic, broad spectrum antibiotics for treating such a common condition could lead to antibiotic resistance developing in an wide range of organisms at sites throughout the body. There is increasing pressure to find alternatives. Experiments have shown that H pylori can be killed by PDT with a range of photosensitisers in vitro28 and H mustelae (which is very similar to H pylori and causes similar pathology in ferrets) can be killed locally in the ferret by filling the stomach with methylene blue and illuminating small areas ex vivo.29 H pylori is usually found on the superficial mucosa of the upper gastrointestinal tract where it is readily accessible endoscopically. Thus it should be feasible to deliver appropriate light doses to all relevant areas, although it will require considerable technical ingenuity to get light to the base of all the folds in the stomach.
PDT is an exciting new way of producing localised tissue necrosis with light which heals remarkably well without cumulative toxicity. It has considerable potential, nonselectively, for treating small tumours that have not spread beyond the wall of the gastrointestinal tract in patients unsuitable for surgery, and selectively, using ALA, for the treatment of dysplasia, as in Barrett's oesophagus. PDT for palliation of advanced cancers, particularly of the oesophagus, is controversial. It is unlikely to become a treatment of choice as other options are simpler and highly effective, but it may have a role in the management of tumour overgrowth in metallic stents that cannot tolerate thermal treatment with the Nd:YAG laser.30 Other applications to pancreatic and bile duct tumours, for adjunctive intraoperative use and for H pylori infection are more speculative at this time, but are certainly worthy of further study.
